Aspergillosis Epidemiology Forecast 2025-2034

Allergic bronchopulmonary aspergillosis affects about 1 to 4 million people worldwide, while chronic pulmonary aspergillosis affects around 3 million people. Invasive aspergillosis is uncommon and typically affects specific patient groups. Aspergillosis can occur in individuals of any age.

Aspergillosis Epidemiology Forecast Report Coverage

The “Aspergillosis Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of aspergillosis. It projects the future incidence and prevalence rates of aspergillosis across various populations. The study covers age, gender, and type as major determinants of the aspergillosis-affected population. The report highlights patterns in the prevalence of aspergillosis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of aspergillosis in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Aspergillosis: Disease Overview

Aspergillosis refers to an infection caused by a group of fungi called Aspergillus. Aspergillosis is reported to primarily impact the lungs, but it can also affect other parts of the body, especially in people with weakened immune systems. Allergic bronchopulmonary aspergillosis (ABPA) causes inflammation in the airways and can lead to respiratory issues. It typically affects people with asthma or cystic fibrosis. Invasive aspergillosis is a severe form of the disease where the fungus invades deeper tissues. Chronic pulmonary aspergillosis is observed in people with lung diseases like tuberculosis or chronic obstructive pulmonary disease (COPD).

Aspergillosis: Treatment Overview

The type of infection and the patient's profile decide the treatment approach. Oral corticosteroids like prednisone are typically used to treat inflammation and control allergic reactions in allergic bronchopulmonary aspergillosis cases. Itraconazole or voriconazole are the commonly prescribed antifungal medications to reduce fungal growth and prevent further fungal colonization. Long-term antifungal therapy is required, usually with drugs like itraconazole, voriconazole, or posaconazole, for the treatment of chronic pulmonary aspergillosis.

Epidemiology

The aspergillosis epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for aspergillosis by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for aspergillosis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Approximately 1 to 4 million people worldwide are affected by allergic bronchopulmonary aspergillosis, and about 3 million people suffer from chronic pulmonary aspergillosis. Invasive aspergillosis is uncommon, typically affecting specific patient groups.
• An estimated 250,000 cases of invasive aspergillosis occur globally each year. This form of aspergillosis has impacted individuals with severe influenza and COVID-19.
• Chronic pulmonary aspergillosis affects about 1,837,272 people every year, with 340,000 (18.5%) of these cases resulting in death, as per a 2024 review.
• In India, there are an estimated 212,502 cases of chronic pulmonary aspergillosis each year, with nearly 90% of the disease burden linked to pulmonary tuberculosis.

Country-wise Aspergillosis Epidemiology

The aspergillosis epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of aspergillosis varies between countries owing to differences in the prevalence of risk factors such as underlying health conditions and immunocompromised states, healthcare systems, and environmental factors, among others. In the United States, surveys and an allergic bronchopulmonary aspergillosis (ABPA) registry estimate that 0.25-0.8% of individuals with asthma and about 7% of patients with cystic fibrosis are affected by ABPA.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of aspergillosis based on several factors.
• Aspergillosis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of aspergillosis are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of aspergillosis epidemiology in the 8 major markets?
• What will be the total number of patients with aspergillosis across the 8 major markets during the forecast period?
• What was the country-wise prevalence of aspergillosis in the 8 major markets in the historical period?
• Which country will have the highest number of aspergillosis patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of aspergillosis during the forecast period of 2025-2034?
• What are the currently available treatments for aspergillosis?
• What are the disease risks, signs, symptoms, and unmet needs of aspergillosis?

This product will be delivered within 3-5 business days.